Advertisement

ImmunoGen Inc. has begun a clinical trial of its small-cell lung cancer treatment, IMGN901.

The randomized Phase 1/2 trial is expected to test the effects of using IMGN901 in combination with carboplatin plus etoposide (C/E) – the current first-line treatment available. The trial will compare the combination treatment and the treatment of C/E alone. The FDA has granted orphan drug status in the U.S. to IMGN901 for its use in treating small-cell lung cancer and Merkel cell carcinoma.

SOURCE

Advertisement
Advertisement